Ad is loading...
ABOS
Price
$2.37
Change
-$0.00 (-0.00%)
Updated
Nov 20 closing price
129 days until earnings call
AURA
Price
$8.75
Change
-$0.00 (-0.00%)
Updated
Nov 20 closing price
110 days until earnings call
Ad is loading...

ABOS vs AURA

Header iconABOS vs AURA Comparison
Open Charts ABOS vs AURABanner chart's image
Acumen Pharmaceuticals
Price$2.37
Change-$0.00 (-0.00%)
Volume$180.52K
CapitalizationN/A
Aura Biosciences
Price$8.75
Change-$0.00 (-0.00%)
Volume$253.02K
CapitalizationN/A
ABOS vs AURA Comparison Chart
Loading...
ABOS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
AURA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
ABOS vs. AURA commentary
Nov 22, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABOS is a Sell and AURA is a Buy.

COMPARISON
Comparison
Nov 22, 2024
Stock price -- (ABOS: $2.31 vs. AURA: $9.03)
Brand notoriety: ABOS and AURA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABOS: 65% vs. AURA: 301%
Market capitalization -- ABOS: $138.78M vs. AURA: $451.06M
ABOS [@Biotechnology] is valued at $138.78M. AURA’s [@Biotechnology] market capitalization is $451.06M. The market cap for tickers in the [@Biotechnology] industry ranges from $463.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.62B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABOS’s FA Score shows that 0 FA rating(s) are green whileAURA’s FA Score has 0 green FA rating(s).

  • ABOS’s FA Score: 0 green, 5 red.
  • AURA’s FA Score: 0 green, 5 red.
According to our system of comparison, AURA is a better buy in the long-term than ABOS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABOS’s TA Score shows that 5 TA indicator(s) are bullish while AURA’s TA Score has 4 bullish TA indicator(s).

  • ABOS’s TA Score: 5 bullish, 5 bearish.
  • AURA’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ABOS is a better buy in the short-term than AURA.

Price Growth

ABOS (@Biotechnology) experienced а -11.49% price change this week, while AURA (@Biotechnology) price change was -9.43% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.74%. For the same industry, the average monthly price growth was -7.78%, and the average quarterly price growth was +1.53%.

Reported Earning Dates

ABOS is expected to report earnings on Mar 31, 2025.

AURA is expected to report earnings on Mar 12, 2025.

Industries' Descriptions

@Biotechnology (-3.74% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AURA($451M) has a higher market cap than ABOS($139M). AURA YTD gains are higher at: 1.919 vs. ABOS (-39.844). ABOS has higher annual earnings (EBITDA): -77.89M vs. AURA (-91.84M). ABOS has more cash in the bank: 200M vs. AURA (174M). AURA has less debt than ABOS: AURA (19.1M) vs ABOS (28.5M). ABOS (0) and AURA (0) have equivalent revenues.
ABOSAURAABOS / AURA
Capitalization139M451M31%
EBITDA-77.89M-91.84M85%
Gain YTD-39.8441.919-2,077%
P/E RatioN/AN/A-
Revenue00-
Total Cash200M174M115%
Total Debt28.5M19.1M149%
TECHNICAL ANALYSIS
Technical Analysis
ABOSAURA
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
84%
Momentum
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
86%
MACD
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
83%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 16 days ago
78%
Bullish Trend 16 days ago
78%
Declines
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 2 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
83%
Aroon
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
ABOS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
AURA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EQNRX22.650.21
+0.94%
MFS Equity Income R1
REIIX14.680.08
+0.55%
West Loop Realty Instl
WRAAX13.260.04
+0.30%
Wilmington Global Alpha Equities A
POLRX47.48N/A
N/A
Polen Growth Investor
GSUKX17.92N/A
N/A
Goldman Sachs International Eq Inc R6

ABOS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABOS has been loosely correlated with INZY. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ABOS jumps, then INZY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABOS
1D Price
Change %
ABOS100%
-2.53%
INZY - ABOS
49%
Loosely correlated
-3.58%
AURA - ABOS
49%
Loosely correlated
+3.20%
BEAM - ABOS
48%
Loosely correlated
-3.72%
GBIO - ABOS
48%
Loosely correlated
-2.22%
ALEC - ABOS
48%
Loosely correlated
+3.44%
More

AURA and

Correlation & Price change

A.I.dvisor indicates that over the last year, AURA has been loosely correlated with VTYX. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if AURA jumps, then VTYX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AURA
1D Price
Change %
AURA100%
+3.20%
VTYX - AURA
56%
Loosely correlated
+0.58%
ABCL - AURA
53%
Loosely correlated
+1.87%
EDIT - AURA
52%
Loosely correlated
-1.66%
ABOS - AURA
49%
Loosely correlated
-2.53%
VRDN - AURA
47%
Loosely correlated
-0.86%
More